Albumin paclitaxel plus carboplatin — Competitive Intelligence Brief

Albumin paclitaxel plus carboplatin (Albumin paclitaxel plus carboplatin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: chemotherapy. Area: Oncology.

phase 2 chemotherapy Oncology Small molecule

Target snapshot

Albumin paclitaxel plus carboplatin (Albumin paclitaxel plus carboplatin) — Chinese Society of Lung Cancer. Albumin paclitaxel is a formulation of paclitaxel, a microtubule inhibitor, which works by binding to tubulin and preventing the formation of microtubules, thereby inhibiting cell division. Carboplatin is a platinum-based chemotherapy drug that works by cross-linking DNA, thereby inhibiting cell division.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Albumin paclitaxel plus carboplatin TARGET	Albumin paclitaxel plus carboplatin	Chinese Society of Lung Cancer	phase 2	chemotherapy
Eloxatin	Oxaliplatin	Yakult Honsha	marketed	Platinum-based chemotherapy agent	DNA	2002-01-01
gemcitabine, cisplatin and bevacizumab	gemcitabine, cisplatin and bevacizumab	Fundacion Clinic per a la Recerca Biomédica	marketed	Combination chemotherapy with anti-angiogenic monoclonal antibody	DNA (gemcitabine, cisplatin); VEGF (bevacizumab)
nab-paclitaxel，Cisplatin	nab-paclitaxel，Cisplatin	Yang Jianjun, PhD	marketed	Chemotherapy combination (taxane + platinum agent)	Microtubules (paclitaxel); DNA (cisplatin)
HAIC of FOLFOX	HAIC of FOLFOX	Tianjin Medical University Cancer Institute and Hospital	marketed	Chemotherapy combination (regional delivery)
Tislelizumab + cisplatin + paclitaxel	Tislelizumab + cisplatin + paclitaxel	First Affiliated Hospital Xi'an Jiaotong University	marketed	PD-1 inhibitor + chemotherapy combination	PD-1 (tislelizumab); DNA (cisplatin); microtubule (paclitaxel)
FOLFIRI + cetuximab	FOLFIRI + cetuximab	Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)	marketed	Chemotherapy combination + monoclonal antibody	EGFR (epidermal growth factor receptor); DNA (via FOLFIRI)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (chemotherapy class)

1. Pfizer · 3 drugs in this class
2. Chengdu New Radiomedicine Technology Co. LTD. · 1 drug in this class
3. Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · 1 drug in this class
4. Chinese Society of Lung Cancer · 1 drug in this class
5. Hutchmed · 1 drug in this class
6. Prof. Massimo Aglietta · 1 drug in this class
7. Sanofi · 1 drug in this class
8. Sun Yat-sen University · 1 drug in this class
9. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
10. Swiss Cancer Institute · 1 drug in this class